23andMe's Business Outlook Tanks by 50% - is it time to buy or sell?

August 20, 5:43 pm

23andMe Holding Co. ($ME), the renowned personal genomics firm known for its direct-to-consumer genetic testing, has recently witnessed a turbulent stock performance. Currently trading at $1.14, the stock has tumbled a staggering 75% from its 52-week peak.

Signs of Waning Consumer Interest

Our recent analysis, on August 18, placed a "Sell" signal on 23andMe with a target price of $0.92. This signal emerges from multiple concerning indicators. Notably, there's been a prolonged reduction in the company's social media followers and a drop in job listings. But more telling is the sharp decline in mobile app downloads, with daily downloads estimated at around 1,100 – a 65% slump since January.

From an investor's standpoint, such a decrease in app downloads implies a potential decrease in new revenue sources. New downloads often mean new customers, new upsell opportunities, and increased engagement. With fewer downloads, it's reasonable to deduce that less fresh revenue is entering the company's ecosystem, posing a stark challenge for growth and profitability projections.

Employee Morale: A Rising Concern

Yet, beyond these metrics, a deeper issue lurks: plummeting employee morale. Over the past year, the company's business outlook has tanked by over 50% according to review sites such as Glassdoor and Indeed. Employees Insider perspectives indicate a palpable dip in culture and morale since 23andMe's public debut. Employees voice concerns about stagnating career trajectories, volatile priorities, an ambiguous business strategy, and an apparent leadership vacuum.

Historical data often underscores a crucial trend: companies displaying a diminishing business outlook typically lag behind those boasting a buoyant one. Given the current trajectory of 23andMe, coupled with a dearth of optimistic alternative data signals, our present stance leans towards a sell signal with a price target at $0.92, marking an 18% potential drop from its existing price.

Yet, as with all market insights, this isn't financial advice. Investors should exercise due diligence and conduct thorough research before making any investment decisions.

Get More Insights

Sign up and get access to a personalized dashboard, deeper insights, AI stock picks, stock alerts, weekly newsletter and much more.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.